[1]
|
Anderson KC. Progress and paradigms in multiple myeloma[J]. Clin Cancer Res, 2016, 22:5419-5427. doi: 10.1158/1078-0432.CCR-16-0625 |
[2]
|
McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651 |
[3]
|
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome[J]. N Engl J Med, 1996, 335:91-97. doi: 10.1056/NEJM199607113350204 |
[4]
|
Child JA, Morgan GJ, Davies FE, et al. Medical research council adult leukaemia working party. High-dose chemo-therapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi: 10.1056/NEJMoa022340 |
[5]
|
Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J]. Blood, 2011, 118:529-534. http://europepmc.org/abstract/MED/21482708 |
[6]
|
Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2003, 349:2495-2502. doi: 10.1056/NEJMoa032290 |
[7]
|
Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA[J]. Blood, 2005, 106:3755-3759. http://www.tandfonline.com/servlet/linkout?suffix=CIT0008&dbid=16&doi=10.1517%2F14656566.7.2.195&key=10.1182%2Fblood-2005-03-1301 |
[8]
|
Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma:a phase Ⅱ study by the Intergroupe Francophone du Myélome[J]. J Clin Oncol, 2014, 32:2712-2717. doi: 10.1200/JCO.2013.54.8164 |
[9]
|
Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplan, 2007, 13:183-196. doi: 10.1016/j.bbmt.2006.09.010 |
[10]
|
Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma:a meta-analysis of phase Ⅲ randomized, controlled trials[J]. J Clin Oncol, 2013, 31:3279-3287. doi: 10.1200/JCO.2012.48.4626 |
[11]
|
Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28:4621-4629. doi: 10.1200/JCO.2009.27.9158 |
[12]
|
Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase Ⅲ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30:2946-2955. doi: 10.1200/JCO.2011.39.6820 |
[13]
|
Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J]. Blood, 2012, 120:1589-1596. http://www.tandfonline.com/servlet/linkout?suffix=CIT0047&dbid=16&doi=10.1080%2F17474086.2018.1437345&key=10.1182%2Fblood-2012-02-408922 |
[14]
|
Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study[J]. Lancet, 2010, 376:2075-2085. doi: 10.1016/S0140-6736(10)61424-9 |
[15]
|
Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma[J]. N Engl J Med, 2014, 371:895-905. doi: 10.1056/NEJMoa1402888 |
[16]
|
Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma[J]. Blood, 2010, 116:679-686. http://europepmc.org/articles/PMC3324254/ |
[17]
|
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi: 10.1056/NEJMoa1611750 |
[18]
|
Attal M, Harousseau JL, Leyvraz S, et al. Maintenance the-rapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108:3289-3294. http://europepmc.org/abstract/MED/16873668 |
[19]
|
Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27:1788-1793. doi: 10.1200/JCO.2008.18.8573 |
[20]
|
Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J]. N Engl J Med, 2006, 354:1021-1030. doi: 10.1056/NEJMoa053583 |
[21]
|
Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalido-mide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities[J]. Blood, 2008, 112:3115-3121. http://www.ncbi.nlm.nih.gov/pubmed/18492953 |
[22]
|
Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma[J]. Blood, 2010, 115:1113-1120. doi: 10.1182/blood-2009-05-222539 |
[23]
|
Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J]. Blood, 2012, 119:7-15. doi: 10.1182/blood-2011-06-357038 |
[24]
|
Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1782-1791. doi: 10.1056/NEJMoa1114138 |
[25]
|
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1770-1781. doi: 10.1056/NEJMoa1114083 |
[26]
|
Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma[J]. Biol Blood Marrow Transplant, 2013, 19:760-766. doi: 10.1016/j.bbmt.2013.01.004 |
[27]
|
Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma[J]. Cancer, 2012, 118:1585-1592. doi: 10.1002/cncr.26422 |